THCBF - OTC
VANCOUVER, April 20, 2020 /PRNewswire/ - THC BioMed Intl Ltd. ("THC BioMed" or the "Company") is pleased to announce that it has reduced the price of its premium indoor-grown cannabis to $4.20 per gram for registered medical patients.
THC BioMed further reports that it has begun the sale and shipment of its THC Kiss cannabis beverage to registered medical patients.
THC Kiss will be rolled out to the recreational market in the coming weeks.
THC Kiss is a cannabis beverage that aims to be an alternative to smoking cannabis and was developed by THC BioMed using proprietary extraction methods invented by THC BioMed.
Each 30ml bottle of THC Kiss contains 10 mg of THC and is available to registered medical patients for $4.20.
THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. THC BioMed is Canada's largest supplier of legal cannabis genetics. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release are made as of the date of this press release and include that (a) THC BioMed will release THC Kiss to the recreational market in the coming weeks and (b) THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
SOURCE THC BioMed